Icon

STALEVO 100 (nda021485)- (25MG;200MG;100MG)

CARBIDOPA; ENTACAPONE; LEVODOPA ORION PHARMA
25MG;200MG;100MG
Yes Yes
2020-Jun-29 Expired
None None
None No
Stalevo, a combination drug consisting of levodopa (aromatic amino acid), carbidopa (aromatic amino acid decarboxylation inhibitor), and entacapone (catechol-O-methyltransferase (COMT) inhibitor) is indicated for the treatment of Parkinson’s disease. Stalevo is to be used: • To substitute (with equivalent strengths of each of the three components) for carbidopa/levodopa and entacapone previously administered as individual products • To replace carbidopa/levodopa therapy (without entacapone) when patients experience the signs and symptoms of end-of-dose “wearingoff” and when they have been taking a total daily dose of levodopa of 600 mg or less and have not been experiencing dyskinesias.
2 0 1
Total Other Developers None
Drugs with Suitability No
25MG;200MG;100MG ** ** - - 1
NDA Sales Available Total Generic Sales Available
Yes 1
ANDA No Generic Co Manufacturer Name Operations Manufacturer Address Country
****** ****** ***** *************** ******* *********** **** ***. *** ** ***, *** ************, **********, ********* ******, ***** (***) ***

Download GenUS Drug Report


Download GenUS Detailed Report


To get detailed report Contact Us

GenUs Advanced Search




Expired
to
Expired
to


Brand Name Generic Name Strength Dosage Route of Administration Innovator ParaIV

Please contact contact@researchdelta.com to get more details.